Table 2.
Uveitis incidence by secukinumab dose in pooled AS clinical trials
| Type of Uveitis | Any Secukinumab, 300 mg (n = 113) | Any Secukinumab, 150 mg (n = 402) | Any Secukinumab, 75 mg (n = 284) | Totala (N = 794) |
|---|---|---|---|---|
| Flares | 1 | 11 | 2 | 14 |
| New onset | 1 | 6 | 5 | 12 |
| Total | 2 | 17 | 7 | 26 |
| EAIR per 100 patient‐years (95% CI) | 1.0 (0.1‐3.7) | 1.8 (1.0‐2.9) | 0.9 (0.4‐1.9) | 1.4 (0.9‐2.0) |
Abbreviation: AS, ankylosing spondylitis; CI, confidence interval; EAIR, exposure‐adjusted incidence rate.
a
Rates reported for preferred terms by using the Medical Dictionary for Regulatory Activities.